FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of May 2021
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca prices
a $7bn bond offering
26 May 2021 07:00 BST
AstraZeneca prices a $7bn bond offering
AstraZeneca PLC ("AstraZeneca") announces that it, and its wholly
owned subsidiary AstraZeneca Finance LLC, priced a six tranche
global bond offering totalling $7bn on 25 May 2021. The
offering is expected to close on 28 May 2021, subject to customary
closing conditions. The transaction, which is a global offering
registered with the US Securities and Exchange Commission ("SEC"),
consists of the following six tranches:
Notes issued by AstraZeneca
●
$1.40bn of
fixed rate notes with a coupon of 0.300%, maturing 26 May
2023;
●
$0.75bn of
fixed rate notes with a coupon of 3.000%, maturing 28 May
2051;
Notes issued by AstraZeneca Finance LLC and fully and
unconditionally guaranteed by AstraZeneca
●
$1.60bn of
fixed rate notes with a coupon of 0.700%, maturing 28 May
2024;
●
$1.25bn of
fixed rate notes with a coupon of 1.200%, maturing 28 May
2026;
●
$1.25bn of
fixed rate notes with a coupon of 1.750%, maturing 28 May 2028;
and
●
$0.75bn of
fixed rate notes with a coupon of 2.250%, maturing 28 May
2031.
The notes maturing in 2024 are not subject to special mandatory
redemption. All of the other notes above will be subject to special
mandatory redemption if the acquisition of Alexion Pharmaceuticals,
Inc. ("Alexion") (the "Alexion Acquisition") is not consummated on
or before 12 March 2022 or if, prior to such date, AstraZeneca
notifies the trustee that we will not pursue the consummation of
the Alexion Acquisition.
AstraZeneca expects to use the net proceeds of the offering to fund
a portion of the purchase price for the Alexion Acquisition, to pay
or refinance a portion of Alexion's indebtedness and to pay related
fees and expenses, or for general corporate purposes, which may
include the refinancing of existing indebtedness.
Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan
Stanley & Co. LLC, Barclays Capital Inc., BNP Paribas,
Citigroup Global Markets Inc., Deutsche Bank Securities Inc., HSBC
Securities (USA) Inc., Mizuho Securities USA LLC, Santander
Investment Securities Inc., Skandinaviska Enskilda Banken AB (publ)
and Société Générale acted as joint
book-running managers on the transaction.
The notes will be issued under AstraZeneca's effective shelf
registration statement on Form F-3, which AstraZeneca and
AstraZeneca Finance LLC filed with the SEC on 24 May 2021. The
offering is being made solely by means of the prospectus contained
within that shelf registration statement, along with a prospectus
supplement forming part of the effective registration statement,
which investors should read.
A copy of the prospectus supplement and accompanying prospectus
relating to the offering can be obtained by contacting Goldman
Sachs & Co. LLC, Prospectus Department, 200 West Street, New
York, NY 10282, by telephone at +1-866-471-2526 or by emailing
[email protected]; J.P. Morgan Securities
LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717 or by calling +1 (866) 803-9204; or Morgan Stanley &
Co. LLC, 180 Varick Street, New York, New York, 10014, Attention:
Prospectus Department, by telephone at +1 (866) 718-1649, or by
email at [email protected]m.
Readers may also download these documents for free by visiting the
Electronic Data Gathering, Analysis, and Retrieval (EDGAR) system
on the SEC website at www.sec.gov.
This announcement shall not constitute an offer to sell or the
solicitation of an offer to buy the securities described herein,
nor shall there be any sale of these securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such jurisdiction.
The bond issuance does not impact AstraZeneca's financial guidance
for 2021.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines in
Oncology and BioPharmaceuticals, including Cardiovascular, Renal
& Metabolism, and Respiratory & Immunology. Based in
Cambridge, UK, AstraZeneca operates in over 100 countries, and its
innovative medicines are used by millions of patients
worldwide.
AstraZeneca contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
26 May 2021
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|